MLTX - Why Is Arthritis-Focused MoonLake Immunotherapeutics Stock Trading Lower Today? | Benzinga
Sunday, MoonLake Immunotherapeutics (NASDAQ: MLTX) released topline results from its global Phase 2 ARGO trial of Nanobody sonelokimab in patients with active psoriatic arthritis (PsA).
The ARGO trial met its primary endpoint with a statistically significant greater proportion of patients treated with either sonelokimab 60mg or 120mg (with induction) achieving an American College of Rheumatology (ACR) 50 response compared to those on placebo ...